Kornimate/medical-research-clean huggingface dataset:
a comparison of dendritic cell content and t-cell phenotype between granulocyte colony-stimulating factor (g-csf) or g-csf + granulocyte macrophage (gm)-csf

Conditions: Hematologic Diseases

Summary: this is a study involving patients who are undergoing allogeneic peripheral blood stem cell transplantation. both donors and recipients are being sought for this study.

patients with leukemia will receive a stem cell transplant, prior to which they will receive medication and/or radiation to destroy all leukemia cells as well as other blood cells. in order to survive this treatment, patients will need to be given the stem cells from another person to replace the blood cells killed by the treatment. the stem cells given to the recipient will be collected from a relative. to increase the number of stem cells in the relative, he/she is given a growth factor to increase the number of stem cells prior to collection. the standard growth factor used is called g-csf(granulocyte colony-stimulating factor ). in this research study, the physician will give the relative either g-csf or a combination of g-csf and gm-csf (granulocyte macrophage (gm)) , another type of growth factor. whether the relative receives g-csf or gm-csf will be determined by chance. the donors will be randomized to one or the other. it is not known if the stem cells and white blood cells collected using one or both growth factors results in more cures for this disease and fewer side effects, such as graft-versus-host disease. the reason for doing the study is to determine if the stem cells and other white blood cells collected are any different when different growth factors are given, and to see how well the patient does. the stem cell transplant will in every other way be the same. the only difference is that if the recipient and donor decide to be in this study, the donor will either be given only g-csf or the combination of g-csf and gm-csf and the recipient will receive the stem cells collected.

Eligibility criteria:
inclusion criteria: * all normal donors for patients undergoing allogeneic peripheral blood stem cell (pbsc) for hematologic diseases will be invited to participate in this research trial. * all patients must meet criteria for transplantation. * final eligibility will be determined by the health professionals conducting this clinical trial. exclusion criteria: * donors for patients undergoing selected or manipulated pbsc grafts are not eligible. * donors who are pregnant or lactating females and donors with a known hypersensitivity to either g-csf or gm-csf will be excluded from this study. * final eligibility will be determined by the health professionals conducting this clinical trial.

Keywords: hematologic diseases
exercise capacity according to coronary microvascular dysfunction and body composition

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)

Summary: the correlation of coronary microvascular function and body composition with cardiopulmonary exercise capacity will be assessed in patients with heart failure with preserved ejection fraction.

we will select the patients with chest pain or ischemic symptoms with non-obstructive coronary artery disease (\<50% stenosis) in coronary angiography and preserved ejection fraction (≥50%) in echocardiography. all patients will undergo body composition analysis and adenosine stress echocardiography with the evaluation of coronary artery blood flow by doppler echocardiography and maximal oxygen consumption (vo2 max) by cardiopulmonary exercise test (cpet). left ventricular end-diastolic pressure will be assessed during coronary angiography. coronary flow reserve (cfr) is defined as the ratio of peak to baseline mean diastolic velocity of coronary blood flow. the correlation of cfr and body composition with cardiopulmonary exercise capacity will be assessed.

Eligibility criteria:
inclusion criteria: * age 20 to 80 * typical/atypical chest pain or ischemic symptoms including dyspnea * no significant coronary artery stenosis (\>50% stenosis) in coronary angiography or computed tomography * left ventricular ejection fraction ≥50% exclusion criteria: * more than moderate valvular heart disease * congenital heart disease * chronic renal failure (estimated glomerular filtration rate \<30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis * asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension * receiving anticancer drugs * vasculitis associated with autoimmune diseases * patients with difficulty in performing exercise load evaluation (treadmill, bicycle ergometer) * atrial fibrillation * atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, wolff-parkinson-white (wpw) patients

Keywords: body composition, cpet, cfr, coronary microvascular dysfunction (cmd), frailty, hfpef
intubation of a pediatric manikin in difficult airway by novice personnel: a comparison of glidescope and airtraq

Conditions: Intubation; Difficult; Edema of the Tongue

Summary: background and aims: glidescope and airtraq were designed to facilitate intubation and to improve teaching intubation. the investigators want to find their efficacy in normal airway, tongue edema and face-to-face orotracheal intubation models by novice personal. material and methods: after kocaeli human researches ethics committee approval, thirty six medical students who were on the beginning of their third year were enrolled in this study. after watching a video about the intubation of one of these devices, they attempted to intubate an adult manikin in three different airway models in a random order; first in normal airway, second, tongue edema and finally, in an entrapped manikin by face-to-face approach with glidescope or airtraq. intubation attempts, insertion and intubation times, success rates, cormack-lehane grades, need of maneuvers of these devices were recorded.

trauma victims mostly had to be intubated at the scene of the area with the paramedics. in a suspect of a cervical trauma, patients must be intubated with the least movement. videolaryngoscopic techniques had several advantages at this condition. we want to investigate which can be used easily by novice personnel.

Eligibility criteria:
inclusion criteria: * medical students at their third year, * novice personnel exclusion criteria: * anesthesists, * anesthesia residents, * skilled investigators of tracheal intubation
independent risk factors analysis and model construction for recurrence after radiofrequency/microwave ablation of colorectal cancer with liver metastases: a retrospective, multicenter trial

Conditions: Colorectal Cancer With Liver Metastases

Summary: this study is a retrospective, multicenter clinical study. the main objective is to analyze the risk factors affecting the recurrence of colorectal cancer patients with liver metastases who received radiofrequency/microwave ablation. finally, we will construct a recurrence risk prediction model based on the risk factors and validated the model.


Eligibility criteria:
inclusion criteria: 1. age：older than 18 years； 2. patients with a single tumor diameter ≤5cm, no more than 3 tumor nodules, and the largest tumor diameter ≤3cm； 3. absence of vessel, bile duct and adjacent organ invasion and distant metastasis; 4. the primary tumor of colorectal cancer has been resected, the liver metastases cannot be resected or the patient is unwilling to undergo surgery (clinical or pathological confirmation); 5. normal coagulation status and liver function child-pugh a or b; 6. liver metastases have not received other antitumor therapy after radiofrequency/microwave therapy (before disease progression); 7. routine laboratory tests were performed before the first rf/microwave treatment; 8. follow up for more than 12 months; 9. obtained free informed consent. exclusion criteria: 1. large tumor, or diffuse intrahepatic metastasis; 2. accompanied by vascular tumor thrombus or invasion of adjacent organs; 3. the primary tumor of colorectal cancer has not been resected, with extrahepatic metastasis; 4. uncorrectable coagulation dysfunction and severe blood abnormalities, those with severe bleeding tendency; 5. intractable massive ascites, cachexia; 6. active infection, especially inflammation of the biliary system; 7. severe liver, kidney, heart, lung, brain and other major organ failure; 8. patients with impaired consciousness or unable to cooperate with treatment; 9. missing follow-up data.

Keywords: colorectal cancer with liver metastases radiofrequency/microwave recurrence
global postural reeducation in chronic low back pain

Conditions: Back Pain; Mechanical Low Back Pain

Summary: the purpose of this study is to evaluate the effectiveness of a global postural reeducation (gpr) program in subjects with chronic low back pain.

approximately 80-85% of individuals will experience low back pain during their lifetime. it is one of the major concerns of current health care. there is evidence for the effectiveness of exercise therapy in patients with chronic low back pain. gpr is a physical therapy method developed in france by philippe emmanuel souchard. although this method is largely used as form of treatment in most countries, few studies showed its clinical effectiveness in chronic low back pain. this is the first randomized controlled trial, with assessor blind that evaluate the gpr effects in chronic low back pain. all outcome measurements are reliability, validated and sensitivity for statistical changes using the visual analogic scale- vas (0-10cm), roland morris questionary, sf36 (quality life questionary) and beck scale (depression symptoms).

Eligibility criteria:
inclusion criteria: * between 18-65 years age, * low back pain (more than 12 weeks) without legs irradiation, * pain between 3-8 cm on a visual analogue scale (0-10cm). exclusion criteria: * fibromyalgia, * pregnancy, * osteoporosis severe, * disc herniation, * patients who had undergone spinal surgical or physiotherapeutic interventions within 3 months prior to baseline assessment.

Keywords: chronic low back pain postural global reeducation randomized physical rehabilitation
the relationship of fetal lung elastography values with the development of respiratory distress in cases of preterm labor

Conditions: Preterm Labor; Respiratory Distress Syndrome

Summary: the aim of this study was to compare fetal lung elastography (fae) values between groups with and without respiratory distress syndrome (rds) in preterm neonates and to evaluate the potential of fae to predict the risk of developing rds.

the evaluate the potential of fetal lung elastography as a non-invasive method to predict and treatment respiratory complications in preterm neonates. fae is an imaging method that measures the elasticity properties of fetal lung tissue using ultrasound technology. this method can be helpful in providing information about the development and respiratory function of the fetal lungs. the advantages of fae are: it is a non-invasive method: fae is performed using ultrasound technology and has no known maternal or fetal harm. it stands as a potentially safe method compared to current invasive tests. it is cost-effective and easy to perform: fae is a procedure performed using existing ultrasound equipment at no separate cost. therefore, it can be easily implemented and repeated in clinical settings. fast results: fae provides fast results by acquiring images in real time. this indicates that fae can be a valuable diagnostic tool in emergency situations or when rapid decision-making is required. a potential predictive tool: the results of this study may indicate that fae values are a potential tool for predicting the risk of developing rds. this could be an important step to develop early diagnosis and treatment strategies to improve the respiratory health of preterm newborns.

Eligibility criteria:
inclusion criteria: * 18-45 years old * single pregnant women who were followed up with a diagnosis of preterm labor between 24-33 weeks and who volunteered and consented to the study * measured at least 24 hours after antenatal corticosteroid and delivered within a maximum of 72 hours after measurement exclusion criteria: * multiple pregnancies * amniotic fluid pathologies * fetal lung and liver diseases * fetal genetic and structural anomalies * signs and diagnoses of systemic maternal diseases * advanced maternal obesity preventing measurement * patients hospitalized with a diagnosis of preterm labor and discharged before delivery * presence of comorbid diseases of pregnancy (gdm, hypertensive diseases of pregnancy, pprom, chorioamnionitis etc.) * pregnant women over 45 years of age, systemic conditions (history of chronic, mental, physical illness, severe renal, hepatic, gastrointestinal acute/chronic inflammatory disease, hyperthyroidism, hypothyroidism, hypertension, type 1/2 dm, history of malignancy, smoking, alcohol use)

Keywords: preterm labor respiratory distress syndrome fetal lung elastography elastography
resistant starch on glucose and insulin sensitivity in individuals with type 2 diabetes

Conditions: Hyperglycemia

Summary: this study will test the effects of resistant starch type 4 on blood sugar and hunger in adults with type 2 diabetes.

to measure the blood glucose response, after an overnight fast, blood samples will be collected before eating and 15, 30, 45, 60, 90, and 120 minutes after eating each bar. the incremental area under the curve was used to calculate glycemic index. the investigators will also measure the second meal effect by measuring the metabolic response (glucose, insulin, and gut hormones) after a standardized lunch two hours following the first assessment.

Eligibility criteria:
inclusion criteria: * type 2 diabetics exclusion criteria: * diagnosed with other metabolic disorders * allergies to wheat * non-smokers

Keywords: diabetes diet fiber
long-term follow-up of patients who have participated in children's oncology group studies

Conditions: Hematopoietic Cell Transplantation Recipient; Leukemia; Solid Tumor

Summary: this clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a children's oncology group study. developing a way to keep track of patients who have participated in children's oncology group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.

primary objectives: i. to develop a mechanism for tracking and retaining patients enrolled on children's oncology group (cog) protocols. ii. to maintain regular, lifetime contact with patients in order to obtain current identification and contact information, and self/parent-reported quality of life and health status. iii. to locate patients who are lost-to-follow-up for cog (or legacy group) protocols targeted for follow-up by the long-term follow-up center (ltfc). iv. to provide current patient contact information and self/parent-reported health status updates to the cog statistics and data center (sdc) and to each patient's cog institution. v. to facilitate collection of protocol-specific outcome data through collaboration with the ltfc oversight committee, the sdc, and the member institutions. outline: this is an umbrella protocol for all long-term follow-up at cog institutions. within 3 months of enrollment on alte05n1, patients receive a packet introducing the long-term follow-up center (ltfc). patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. the health status update form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. patients may respond by use of postage prepaid envelopes, secure online form, or 24-hour toll-free telephone number. after initial contact, the ltfc will contact the patient annually.

Eligibility criteria:
inclusion criteria: * the patient must reside in the u.s. on the date of enrollment to alte05n1 * all patients and/or their parents or legal guardians must sign a written informed consent * all institutional, food and drug administration (fda), and national cancer institute (nci) requirements for human studies must be met
pharmacokinetic study of sparc1613 and reference1613 in subjects with locally recurrent or metastatic breast cancer

Conditions: Recurrent or Metastatic Breast Cancer

Summary: sparc1613 is chemotherapeutic agent with a wide spectrum of anti-tumor activity. it is used extensively in the treatment of advanced carcinomas of the breast, ovaries, lung, and other solid tumors.this is pharmacokinetic study of sparc1613 and reference1613.

the purpose of this study is to evaluate level of test medication with respect to time in the body, and safety when compared with the reference medication subject will be randomly assigned to receive an intravenous infusion of either sparc1613 delivered over 25 (±1) minutes or reference1613 delivered over 30 (±1) minutes

Eligibility criteria:
inclusion criteria: * the subject has given written, informed consent and is available for the duration of study * histologically or cytologically confirmed diagnosis of breast cancer * male or female aged ≥ 18 years * females subjects of child-bearing potential must have a negative urine pregnancy test * female subjects must be non-lactating and non-breastfeeding * subject must be willing and able to comply with scheduled visits, treatment plan and laboratory testing exclusion criteria: * known hypersensitivity to either of the study drugs or their excipients * inability to undergo venipuncture and/or tolerate venous access * pre-existing clinically significant peripheral neuropathy * positive laboratory exclusion test (hiv, hbsag, or hcv) * treatment with investigational agents or participation in clinical trial within 30 days of study entry
a trial comparing moxifloxacin versus levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease

Conditions: Pelvic Inflammatory Disease

Summary: to assess the efficacy and safety of oral moxifloxacin compared to oral levofloxacin plus oral metronidazole in uncomplicated pelvic inflammatory disease (pid)


Eligibility criteria:
inclusion criteria: * diagnosis of uncomplicated pid based on the absence of pelvic or tubo-ovarian abscess at pelvic ultrasound and/or laparoscopic examination. exclusion criteria: * subjects with impaired liver and renal function; known hypersensitivity to study drugs, related compounds or any of the excipients.

Keywords: uncomplicated pelvic inflammatory disease
individual patient expanded access ind of hope biosciences autologous adipose-derived mesenchymal stem cells for treatment of sci

Conditions: Spinal Cord Injury at C5-C7 Level

Summary: this study is expanded access to an investigational new drug (ind) for an individual patient with spinal cord injury (sci) at cervical spine 5-6 (c 5-6) designed to provide access to autologous adipose-derived mesenchymal stem cells (hb-admscs)

this is an expanded access single-dose study with the primary goal of treatment submitted at the request of an individual patient with complete c5-6 spinal cord injury (sci) resulting in quadriplegia who does not qualify for any current clinical trials and for whom there are no other fda approved fully restorative treatments. the overall objective of this study is to evaluate patient's response, adverse events and serious adverse events (ae/saes), and cell expansion characteristics of a single intravenous (iv) infusion of autologous adipose-derived mesenchymal stem cells (hb-admscs) in a subject with complete sci resulting in quadriplegia.

Eligibility criteria:
inclusion criteria: * cognitively intact, capable of giving informed consent * clinical diagnosis of a non-penetrating traumatic sci * asia impairment scale grade of a, b, or c exclusion criteria: 1. prior history of: * brain injury * recent or ongoing infection * clinically significant cardiovascular, lung, renal, hepatic or endocrine disease, * neurodegenerative disorders * cancer * immunosuppression as defined by wbc\<3,000 cells/ml at baseline screening, * hiv+ * chemical or etoh dependency 2. having a contraindication to mri scans 3. other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or hb-admsc administration 4. participation in other interventional research studies 5. unwillingness to return for follow-up visits

Keywords: sci stem cells quadriplegia spinal cord injury paralysis mscs
evaluating pain control strategies in postpartum patients on opioid use disorder medications.

Conditions: Substance Use Disorder (SUD)

Summary: the purpose of this study is to investigate the efficacy of three different modalities of post-operative pain control in parturient with opioid use disorders. the investigators aim to determine whether the different approach utilized show better outcomes with pain management and if there are any association with reduction of symptoms of anxiety, depression, and overall well-being.


Eligibility criteria:
inclusion criteria: * inclusion criteria include being a parturient with substance use disorder (sud) and age 18-35 exclusion criteria: * exclusion criteria include having a diagnosed medical condition(allergies to medication, pathology such as severe aortic stenosis excluding patients from receiving an epidural etc) that will exempt patient from intervention arm of the study.

Keywords: pain conrtrol substance use disorder parturient
collaborative care for anxiety and depression in epilepsy

Conditions: Epilepsy; Anxiety; Depression

Summary: this is a randomized effectiveness/implementation trial comparing a 24-week neurology-based collaborative care intervention to usual neurology care among 60 adults with epilepsy.

the intervention is a 24-week, evidence-based collaborative care model initiated around the time of a neurology visit. the collaborative care team roles include the care manager/social worker and psychiatrist who interact with the patient participant and the patient's neurologist/neurology provider.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures * males and females; age \>= 18 years * \* diagnosis of epilepsy: epilepsy diagnosis based on neurology clinician impression or eeg findings * anxiety or depression symptoms * receiving clinical neurological care at atrium health exclusion criteria: * current participation in another treatment of intervention study * cognitive limitations precluding completion of anxiety and depression self-report instruments on paper, electronically, or by interview * comorbid medical condition with life expectancy less than 6 months * not a good candidate for collaborative care due to: * active ongoing treatment by a psychiatrist * active suicidal ideation * history of past suicide attempt and: * receiving ongoing psychotherapy or * has seen a psychiatrist in the past year * history of suicide attempt in the past year and: * currently prescribed 2 or more psychotropic medications for psychiatric indication (not merely as a hypnotic) and not felt to be a good candidate for collaborative care based on the judgement of the investigators * unstable drug or alcohol abuse for the third aim (sustainability supplement: intervention only care delivery exploratory study supplement) - the participants meeting the following criteria may participate * individuals who meet the above inc-exc criteria and have completed the control arm of a collaborative care research study - nct05559749 - nct05353452 or * individuals who meet the above inc-exc criteria except rather than having a diagnosis of epilepsy; they have a diagnosis of functional neurological disorder with seizures

Keywords: quality of life collaborative care